What's in Ferrosan AS's pipeline?

Ferrosan AS has 3 drugs in our index: 3 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Ferrosan AS's portfolio?

No competitive overlap detected.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/ferrosan-as.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-06-10 · How we verify

Ferrosan AS — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ferrosan AS pipeline: 3 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

3 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Ginger-Avocado-Soya	Ginger-Avocado-Soya	marketed			Nutritional supplement / Dietary supplement
Glucosamine sulphate	Glucosamine sulphate	marketed
Ginger-ibuprofen	Ginger-ibuprofen	marketed	NSAID with herbal adjunct	COX-1, COX-2 (ibuprofen component); multiple inflammatory pathways (ginger component)	Pain management, Inflammation

Therapeutic area mix

Nutritional supplement / Dietary supplement · 1
Pain management, Inflammation · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Ferrosan AS:

Cite this brief

Drug Landscape (2026). Ferrosan AS — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/ferrosan-as. Accessed 2026-06-10.